Gary Patou, Director at Xenon Pharmaceuticals Inc. (XENE), bought 5,000 shares at $3.00 ($15K) on 2017-08-08, disclosed to the SEC on 2017-08-10.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| XENE | SELL | 2023-12-15 | $624K | — | Filing → |
| XENE | SELL | 2023-12-15 | $1.0M | — | Filing → |
| XENE | SELL | 2022-11-28 | $276K | — | Filing → |